Robert L Redner MD
Professor, Medicine, University of Pittsburgh School of Medicine
Join to view full profile
5115 Centre AvenueUpmc Cancer PavillionPittsburgh, PA 15232
Phone+1 412-692-4724
Dr. Redner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
Harvard Medical SchoolClass of 1980
Certifications & Licensure
CA State Medical License 1983 - Present
PA State Medical License 1991 - 2026
MD State Medical License 1984 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
Clinical Trials
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
- A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Jan 01
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Publications & Presentations
PubMed
- 17 citationsZiftomenib in Relapsed or Refractory-Mutated AML.Eunice S Wang, Pau Montesinos, James Foran, Harry Erba, Eduardo Rodríguez-Arbolí
Journal of Clinical Oncology. 2025-11-01 - 1 citationsA Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.Eric D Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow
Cancer Research Communications. 2025-07-01 - 6 citationsMolecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03
Grant Support
- Characterization Of A Novel Translocation Product In APLNational Cancer Institute2006–2009
- Calcitriol &Dexamethasone For Myelodysplastic SyndromesFood And Drug Administration2004
- Vitamin D And Dexamethasone In Myelodysplastic SyndromesNational Cancer Institute2002–2003
- Novel Translocation Product In APLNational Cancer Institute1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
